Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.

By R. Goldbach-Mansky, Natalie J. M. Dailey, Scott W. Canna, A. Gelabert, Janet Jones, B. Rubin, H. J. Kim, C. Brewer, C. Zalewski, E. Wiggs and 30 more. New England Journal of Medicine, 2006

830 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/7a32a0b3f6ea700d1b067c2b6ac680715b029757

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. M. Lamkanfi
2. D. Remick
3. C. A. Dinarello

In Molecular Biology

1. M. Lamkanfi
2. J. Tschopp
3. V. Dixit
4. T. Mak
5. T. Berger
6. David Mcilwain
7. C. A. Dinarello
8. A. Simon

In Surgery

1. J. Tschopp
2. M. Lamkanfi
3. V. Dixit
4. T. Mak
5. T. Berger
6. David Mcilwain

Citations in the corpus

• Anti-inflammatory Agents: Present and Future (2010, neutral): “, 2008) Cryopyrin Associated Periodic Syndromes (Goldbach-Mansky et al., 2006; Hoffman et al., 2008; Lachmann et al., 2009) Hyper IgD Syndrome, Mevalonic Aciduria (Bodar et al.”
• NLRP3 inflammasome: From a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases (2015, background): “…LRR, leucine-rich-repeat olymorphonuclear leukocytes; POP, PYD-only proteins; PRRs, pattern-recognition MCs, smooth muscle cells; TLRs, toll-like receptors; TNF, tumor necrosis factor; Trx, unfolded protein response eing Biology (B2A), UMR-8256/INSERM ERL-1164, Université Pierre et Marie Curie,”
• Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS) (2011, background): “…or IL-1 receptor antagonist, are specifically associated with IL-1 overproduction or excessive IL-1 signaling, and IL-1 blockade in these fever syndromes results in normalization of inflammatory parameters and robust clinical responses (Hoffman et al., 2004; Goldbach-Mansky et al., 2006).”
• Mechanisms and functions of inflammasomes. (2014, background): “, 2012), anakinra (Goldbach-Mansky et al., 2006), and canakinumab (Kuemmerle-Deschner et al.”
• A pilot study of IL-1 inhibition by anakinra in acute gout (2007, background): “Affected patients respond dramatically to IL-1 inhibition [12,13], suggesting that IL-1β plays a crucial role in the pathogenesis of inflammation in these conditions.”
• Caspase functions in cell death and disease. (2013, background): “CAPS patients also respond well to IL-1b antagonists (Hawkins et al. 2003, 2004a,b; Hoffman et al. 2004, 2008; Goldbach-Mansky et al. 2006, 2008; Hoffman 2009; Lachmann et al. 2009b), although the disease is also ameliorated by caspase-1 inhibition (Stack et al. 2005).”